Medical Advocates
ARV/HAART
  Starting Therapy 
              

General Reports
 When to Start
 Number of Drugs
 Dosing
First-Line Regimens
 Drug Sequencing
 Quality of Life


 
 
HAART Main Page Main New/Newsworthy Home Page
Last Update:  November 25, 2008
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
      Books
 
  FULL-TEXT BOOK CHAPTER
 How to start with HAART
 Hoffmann C
HIV Medicine-2003 Hofflmann C, Kamps, BS (editors) Amedeo Group 2003
On-Line Book
 
     Journal Papers, Abstracts, and Commentaries
 
 
Disparities in Reported Reasons for Not Initiating or Stopping Antiretroviral Treatment Among
a Diverse Sample of Persons Living with HIV.
Johnson MO, Chesney MA, Neilands TB, et al
J Gen Intern Med. 2008 Nov 18
 Abstract
 
First antiretroviral therapy regimen in HIV-infected patients. Durability and factors associated
with therapy changes.
de la Torre J, Santos J, Perea-Milla E, et al
Enferm Infecc Microbiol Clin. 2008 Aug-Sep;26(7):416-22.
 Abstract
 
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.
Baker JV, Peng G, Rapkin J, et al 
AIDS. 2008 Apr 23;22(7):841-8.
 Abstract

Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and
HIV-HCV infection.
Cooper CL, Mills E.
Int J STD AIDS. 2007 Aug;18(8):546-50.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
 Optimal Timing and Duration of Induction Therapy for HIV-1 Infection.
 Curlin ME, Iyer S, Mittler JE. 
PLoS Comput Biol. 2007 Jul 13;3(7):e133
Paper
 
A WEEK-IN-REVIEW FEATURED REPORT
CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy
in Persons with Sustained Virologic Suppression.
Moore RD, Keruly JC.
Clin Infect Dis. 2007 Feb 1;44(3):441-6
 Abstract
 
Immunological and Virological Impact of Highly Active Antiretroviral Therapy Initiated during
Acute HIV-1 Infection.
Streeck H, Jessen H, Alter G, et al
J Infect Dis. 2006 Sep 15;194(6):734-9.
Abstract
 
Early initiation of highly active antiretroviral therapies for AIDS: Dynamic choice with
endogenous and exogenous learning.
Lasserre P, Moatti JP, Soubeyran A.
Health Econ. 2005 Dec 9;
Abstract

FULL-TEXT PDF ARTICLE
 Antiretroviral Therapy: The Naïve Patient
Gallant JE
The Hopkins HIV Report, March 2004 Vol 16. No 2
 Paper
 
     Conference Reports, Abstracts, and Posters
 
  POSTER
 Early Initiation of HAART during Primary HIV Infection Enhances CD127 Expression and
Proliferative Capacities of HIV-specific CD8+ T Cells
 C Lecuroux I Girault, O Lambotte, et al
(15th CROI)
 PDF Poster    Abstract
When to Start Therapy
 
     Books
 
  FULL-TEXT BOOK CHAPTER
How to start with HAART
Hoffmann C
HIV Medicine-2003 Hofflmann C, Kamps, BS (editors) Amedeo Group 2003
On-Line Book
 

     Journal Papers, Abstracts, and Commentaries

 
When to Start Antiretroviral Therapy?
Wilkin TJ, Gulick RM.
Clin Infect Dis. 2008 Nov 6.
 Abstract
 
When to start antiretroviral treatment: a changing equation.
Highleyman L  .
BETA. 2008 Summer;20(4):17-26.
 Abstract
 
Antiretroviral therapy: when to start and which drugs to use.
Anderson AM, Lennox JL.
Curr Infect Dis Rep. 2008 Jul;10(4):332-9.
 Abstract

Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends
within 24 months of the onset of acute retroviral syndrome.
Voirin N, Routy JP, Smith D, et al
HIV Med. 2008 Jul;9(6):440-4.
Abstract
 
When to start antiretroviral therapy: a swinging pendulum
Gallant JE.
 Top HIV Med. 2008 Jun-Jul;16(2):82-8.
 Abstract
 
Determinants of HIV progression and assessment of the optimal time to initiate highly active
antiretroviral therapy: PISCIS Cohort (Spain).
Jaén A, Esteve A, Miró JM, et al 
J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20.
 Abstract
 
Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses.
Hicks CB, Gay C, Ferrari G.
Clin Exp Immunol. 2007 Jun 21;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
When to initiate antiretroviral therapy and what to start with?
Viget N, Yazdanpanah Y.
Rev Prat. 2006 May 15;56(9):953-63.
 Abstract
 
Starting or changing therapy – a prospective study exploring antiretroviral decision-making.
Fehr JS, Nicca D, Sendi P, Wolf E, et al 
Infection. 2005 Aug;33(4):249-56.
 Abstract
 
HIV Antiretroviral Treatment: Early Versus Later.
Mauskopf J, Kitahata M, Kauf T, Richter A, Tolson J.
J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):562-569
 Abstract
 
When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients.
Wood E, Hogg RS, Harrigan PR, Montaner JS.
Lancet Infect Dis. 2005 Jul;5(7):407-414.
 Abstract
 
The Case for Earlier Treatment of HIV Infection.
Holmberg SD, Palella FJ Jr, Lichtenstein KA, Havlir DV. 
Clin Infect Dis. 2004 Dec 1;39(11):1699-704
 Abstract


Mortality in HIV-Seropositive versus -Seronegative Persons in the Era of Highly
Active Antiretroviral herapy: Implications for When to Initiate Therapy.
Wang C, Vlahov D, Galai N, et al
J Infect Dis. 2004 Sep 15;190(6):1046-54.
 Abstract
 
Initiation of Antiretroviral Therapy During Recent HIV-1 Infection Results in Lower
Residual Viral Reservoirs.
Pires A, Hardy G, Gazzard B, Gotch F, Imami N.
J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):783-790.
 Abstract
 
Initiating HIV therapy. Timing is critical, controversial.
Volberding PA. 
Postgrad Med. 2004 Feb;115(2):15-8, 21, 24-6.
Abstract
 
Improved outcomes with earlier initiation of highly active antiretroviral therapy among
human immunodeficiency virus-infected patients who achieve durable virologic suppression:
longer follow-up of an observational cohort study.
Sterling TR, Chaisson RE, Keruly J, et al
J Infect Dis. 2003 Dec 1;188(11):1659-65.
Abstract
 
When to Begin Highly Active Antiretroviral Therapy? Evidence Supporting Initiation of
Therapy at
CD4+ Lymphocyte Counts <350 cells/microL.
Kaplan JE, Hanson DL, Cohn DL, et al
Clin Infect Dis. 2003 Oct 1;37(7):951-958.
 Abstract

When to initiate highly active antiretroviral therapy: a cohort approach.
Ahdieh-Grant L, Yamashita TE, Phair JP,  et al
Am J Epidemiol 2003 Apr 15;157(8):738-46
 Abstract

Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+
Cell Strata.
Palella FJ, Deloria-Knoll M, Chmiel JS, et al.
Ann Intern Med 2003 Apr 15;138(8):620-6
 Abstract

Initiation of Highly Active Antiretroviral Therapy at CD4+ T Lymphocyte Counts of >350
cells/mm3: Disease Progression, Treatment Durability, andDrug Toxicity.
Sterling TR, Chaisson RE, Moore RD.
Clin Infect Dis 2003 Mar 15;36(6):812-5
 Abstract

Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median
period of 35.5 months in 60% of the patients.
Van Vaerenbergh K, Harrer T, Schmit JC, et al.
AIDS Res Hum Retroviruses 2002 Apr 10;18(6):419-26
 Abstract


FULL-TEXT PDF ARTICLE
 Continuing debate over HIV therapy initiation.
Idemyor V.
HIV Clin Trials 2002 Mar-Apr;3(2):173-6
 Paper

Predictors of use of highly active antiretroviral therapy (HAART) among persons with AIDS
in san francisco, 1996-1999.
Hsu LC, Vittinghoff E, Katz MH, Schwarcz SK.
J Acquir Immune Defic Syndr 2001 Dec 1;28(4):345-50
Abstract
 
"I will start treatment when I think the time is right": HIV-positive gay men talk
about their decision not to access antiretroviral therapy.
Gold RS, Ridge DT
AIDS Care 2001 Dec;13(6):693-708
 Abstract
 

FULL-TEXT ARTICLE
The case against a when-to-start antiretroviral therapy trial
Schouten J T
RITA Vol 7, No 1  Summer 2001
 Paper

The reasoning behind decisions not to take up antiretroviral therapy in Australians
infected with HIV.
Gold RS, Hinchy J, Batrouney CG.
Int J STD AIDS 2000 Jun;11(6):361-70
Abstract
 

     Conference Reports, Abstracts, and Posters

 
Do the disadvantages of late initiation of HAART persist in patients achieving and maintaining viral load
(VL) suppression for a year on HAART?
Waters LJ, Fisher M, Anderson J, et al
(Ninth International Congress on Drug Therapy in HIV Infection)
 Abstract
 
POSTER
 Early Success of ART in a Sub-Saharan African Cohort
F Semitala, A Kambugu, E Katabira, et al
(13 CROI)
 PDF Poster     Abstract

Estimating the Optimum CD4 Threshold for Starting HAART in ART-naïve HIV-infected
Individuals
 J Sterne, M May, D Costagliola, et al
 (13 CROI)
Abstract
 
  Initiation of HAART during Primary HIV-1 Infection Results in Better Restoration and
Maintenance of Mucosal CD4+ T Cells
M Guadalupe, E Reay, S Sankaran, et al
(13 CROI)
 Abstract
Early Therapy
 

     Journal Papers, Abstracts, and Commentaries

  The Effects of Early Antiretroviral Therapy and Its Discontinuation on the HIV-Specific
Antibody Response.
Killian MS, Norris PJ, Rawal BD, et al 
AIDS Res Hum Retroviruses. 2006 Jul;22(7):640-7
Abstract
Number of Drugs
     
Quadruple Drug Therapy
 
  A WEEK-IN-REVIEW FEATURED REPORT
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating
quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B, Cooper DA, Lampe FC, et al
Clin Infect Dis. 2007 Aug 1;45(3):381-90.
 Abstract
 
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection:
a randomized controlled trial.
Gulick RM, Ribaudo HJ, Shikuma CM, et al
JAMA. 2006 Aug 16;296(7):769-81.
 Abstract
 
A randomized study comparing a three- and four-drug HAART regimen in
first-line therapy (QUAD study).
Orkin C, Stebbing J, Nelson M, et al
J Antimicrob C J Antimicrob Chemother. 2004 Dec 17
 Abstract
 
Triple Drug Therapy

     Conference Reports, Abstracts, and Posters

  POSTER
An Updated Systematic Overview of Triple Combination Therapy in
Antiretroviral-naïve HIV-infected Adults
JA. Bartlett, MJ Fath, R DeMasi, et al
(12 CROI)
 PDF Poster     Commentary
 
Multiple Drugs

     Journal Papers, Abstracts, and Commentaries

  Rates of Disease Progression among Human Immunodeficiency Virus-Infected Persons
Initiating Multiple-Drug Rescue Therapy.
Lee N, Hogg RS, Yip B, et al
J Infect Dis. 2003 Jul 1;188(1):137-41.
 Abstract
 
FULL-TEXT ARTICLE
 Systematic review and meta-analysis of evidence for increasing numbers of
drugs in antiretroviral combination therapy
Jordan R,  Gold L, Cummins C, Hyde C
BMJ 2002;324:757
Paper
 
     Conference Reports, Abstracts, and Posters
 
  POSTER
 Efficacy and Safety of Dual-PI Regimens for the Treatment of ART-naïve HIV-1 Subjects:
2IP ANRS 127,a Randomized Pilot Study
R Landman, C Chazallon, D Descamps, et al
 (15th CROI)
 PDF Poster    Abstract
 
3-4 Drugs vs 2 Drugs

     Journal Papers, Abstracts, and Commentaries

  Three- or four- versus two-drug antiretroviral maintenance regimens for HIV
infection.
Rutherford GW, Feldman KA, Kennedy GE
Cochrane Database Syst Rev 2000;(2):CD002037
 Abstract
Dosing
 

     Journal Papers, Abstracts, and Commentaries
 

  Daily dosing of highly active antiretroviral therapy.
Rosenbach KA, Allison R, Nadler JP.
 Clin Infect Dis 2002 Mar 1;34(5):686-92
 Abstract
Drug Sequencing
 
     Journal Papers, Abstracts, and Commentaries
 
 
Relation between sequence and structure of HIV-1 protease inhibitor complexes:
a model system for the analysis of protein flexibility.
Zoete V, Michielin O, Karplus M.
J Mol Biol 2002 Jan 4;315(1):21-52
 Abstract
 
A rational approach to the selection and sequencing of nucleoside/nucleotide
analogues: a new paradigm.
Lange J.
Antivir Ther 2001;6 Suppl 3:45-54
 Abstract

 FULL-TEXT PDF ARTICLE
Health-related quality of life in individuals infected with HIV in the era of HAART.
Miners AH, Sabin CA, Mocroft A, et al.
HIV Clin Trials 2001 Nov-Dec;2(6):484-92
 Paper

HAART Main Page Main New/Newsworthy Home Page

 Starting Therapy in ARV-Naive Patients